Published: August 2023
According to a recently published report by Roots Analysis, the rising demand for more efficient and homogenous antibody drug conjugates is driving the ADC technology market growth
The global ADC technology market size was estimated at USD 1.18 billion in 2023 and is expected to reach over USD 4.37 billion by 2035, growing at a CAGR of 11.5% in the forecast period 2023-2035.
Antibody drug conjugates are a complex and versatile form of anti-cancer therapy, which have been proven to be more effective and less toxic to patients. Such interventions are designed to identify specific antigens that are expressed on the surface of cancer (target) cells so that the effects of the cytotoxin / drug are focused on the elimination of only the cancerous cells. Owing to the target specificity component, the approach reduces the chances of damaging normal cells. Over the years, this class of therapeutics has undergone several improvements, most of which were focused on how the highly potent cytotoxic component could be attached to the segment that confers specificity (the antibody). The physical attachment of the aforementioned components is facilitated in a process that is commonly referred to as conjugation, or bioconjugation.
Browse 140+ figures and 200+ market data tables spread across 400+ pages and detailed Table of Content on “ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies (2nd Edition) by Generation of ADC Technology, Type of Conjugation, Type of Linker and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035” here: https://www.rootsanalysis.com/reports/adc-technologies-market/287.html
One of the key drivers of the ADC technology market size is the increasing number of investments and collaborations between leading players. In order to fulfil the growing demand for antibody drug conjugates, significant investments have been made in the ADC technology market. In fact, various large and mid-sized players have invested heavily, to gain access to the novel and innovative ADC technologies, for the production of efficient and homogeneous ADCs. One such example of player includes Synaffix. Over the years, Synaffix has entered into various licensing agreements, through which the company is anticipated to receive a sum of USD 5.35 billion in terms of upfront and milestone payments.
Although, antibody drug conjugates is a very promising drug class for targeting oncological disorders. However, ADC development and manufacturing is challenging and cost intensive process. Owing to the complex structure of antibody drug conjugates, the market growth of this industry has not reached it complete potential. Moreover, the number of side effects associated with the antibody drug conjugates asks for very selective types of conjugation and linker technologies, thereby limiting the growth of ADC technology market.
Despite the challenges, several growth factors continue to drive the ADC technology market forward. One notable factor is the generation of site-specific conjugation technologies. These technologies have the potential to develop more stable and precise antibody drug conjugates. Moreover, the resulting ADCs offer lesser off-target effects and increased concentration towards the tumor sites. In fact, owing to the ever evolving domain of ADC technology, several ADCs have been introduced to the development pipeline that are more stable and are homogenous in nature.
The ADC Technology market report also includes detailed profiles of key players (listed below) that offer ADC technologies products:
You Can Download Free Sample PDF Copy of This Report At:
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES